Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 18, Issue 11, 2016, Pages 1134-1137

  Mathieu, C ^a   Herrera Marmolejo, M ^b   Gonzalez Gonzalez J G ^c   Hansen, L ^d   Chen, H ^e   Johnsson, E ^f   Garcia Sanchez, R ^e   Iqbal, N ^e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Servicio de Endocrinología   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^d BRISTOL MYERS SQUIBB   (United States)

^e ASTRAZENECA   (United Kingdom)

^f Global Medicines Development   (Sweden)

Author keywords

dapagliflozin; DPP 4 inhibitor; metformin; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SAXAGLIPTIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ADAMANTANE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; DIPEPTIDE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN;

ABNORMAL LABORATORY RESULT; ADD ON THERAPY; ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

ADAMANTANE; ADULT; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84990243738     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12737     Document Type: Article

References (16)

1. American Diabetes Association. 7. Approaches to glycemic treatment. Diabetes Care. 2016;39(suppl 1):S52–59.
2. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2016 executive summary. Endocr Pract. 2016;22:84–113.
3. DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36:3169–3176.
4. Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009;32:S223–S231.
5. Mathieu C, Ranetti AE, Li D, et al. A randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38:2009–2017.
6. Tsiatis AA, Davidian M, Zhang M, Lu X. Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Stat Med. 2008;27:4658–4677.
7. Zhang M, Tsiatis AA, Davidian M. Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics. 2008;64:707–715.
8. Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metab. 2015;17:1075–1084.
9. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508–2515.
10. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267–1282.
11. Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015;37:1773–1788.
12. Jabbour SA, Hardy E, Sugg J, Parikh S, Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740–750.
13. Matthaei S, Aggarwal N, Garcia-Hernandez P, et al. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. Diabetes Obes Metab. 2016. DOI: 10.1111/dom.12741.
14. U.S. Food and Drug Administration. FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. 2015. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm. Accessed April 15, 2016.
15. US Food and Drug Administration. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015. http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Accessed April 15, 2016.
16. American Association of Clinical Endocrinologists. AACE/ACE scientific and clinical review: association of SGLT2 inhibitors and DKA. 2015. http://resources.aace.com/in-the-news/aaceace-scientific-and-clinical-review-association-sglt2-inhibitors-and-dka. Accessed April 15, 2016.